Skip to main content
Erschienen in: Tumor Biology 11/2014

01.11.2014 | Research Article

Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women

verfasst von: Yuan Wang, Ying Gao, Munkhzul Battsend, Kexin Chen, Wenli Lu, Yaogang Wang

Erschienen in: Tumor Biology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

The optimal approach regarding breast cancer screening for Chinese women is unclear due to the relative low incidence rate. A risk assessment tool may be useful for selection of high-risk subsets of population for mammography screening in low-incidence and resource-limited developing country. The odd ratios for six main risk factors of breast cancer were pooled by review manager after a systematic research of literature. Health risk appraisal (HRA) model was developed to predict an individual’s risk of developing breast cancer in the next 5 years from current age. The performance of this HRA model was assessed based on a first-round screening database. Estimated risk of breast cancer increased with age. Increases in the 5-year risk of developing breast cancer were found with the existence of any of included risk factors. When individuals who had risk above median risk (3.3 ‰) were selected from the validation database, the sensitivity is 60.0 % and the specificity is 47.8 %. The unweighted area under the curve (AUC) was 0.64 (95 % CI = 0.50–0.78). The risk-prediction model reported in this article is based on a combination of risk factors and shows good overall predictive power, but it is still weak at predicting which particular women will develop the disease. It would be very helpful for the improvement of a current model if more population-based prospective follow-up studies were used for the validation.
Literatur
1.
Zurück zum Zitat Chen XY, Kong ZL. Chinese Cancer Registry annual report 2009. Beijing: Military Medical Science Press; 2010. p. 26–8. Chen XY, Kong ZL. Chinese Cancer Registry annual report 2009. Beijing: Military Medical Science Press; 2010. p. 26–8.
2.
Zurück zum Zitat Huang ZZ, Chen WQ, Wu CX, Zheng RS, Chen JG, Yang NN, et al. Incidence and mortality of female breast cancer in China—a report from 32 Chinese cancer registries 2003–2007. Tumor. 2012;32(6):435–9. Huang ZZ, Chen WQ, Wu CX, Zheng RS, Chen JG, Yang NN, et al. Incidence and mortality of female breast cancer in China—a report from 32 Chinese cancer registries 2003–2007. Tumor. 2012;32(6):435–9.
3.
Zurück zum Zitat Chen WQ, Zheng RS, Zeng HM, Zhang SW, Li GL, Wu LY, et al. Incidence and mortality of breast cancer in China, 2008. Thorac Cancer. 2013;4(1):59–65.CrossRef Chen WQ, Zheng RS, Zeng HM, Zhang SW, Li GL, Wu LY, et al. Incidence and mortality of breast cancer in China, 2008. Thorac Cancer. 2013;4(1):59–65.CrossRef
4.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef
5.
Zurück zum Zitat Hillner BE. Annual mammographic screening beginning at 40 years of age did not significantly reduce breast cancer mortality after 10 years in women. Evid Based Med. 2007;12(3):71.PubMedCrossRef Hillner BE. Annual mammographic screening beginning at 40 years of age did not significantly reduce breast cancer mortality after 10 years in women. Evid Based Med. 2007;12(3):71.PubMedCrossRef
6.
Zurück zum Zitat Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality. Int J Cancer. 1996;66(6):727–31.PubMedCrossRef Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality. Int J Cancer. 1996;66(6):727–31.PubMedCrossRef
7.
Zurück zum Zitat Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Follow-up after 11 years—update of mortality results in the Stockholm Mammographic Screening trial. Breast Cancer Res Treat. 1997;45(3):263–70.PubMedCrossRef Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Follow-up after 11 years—update of mortality results in the Stockholm Mammographic Screening trial. Breast Cancer Res Treat. 1997;45(3):263–70.PubMedCrossRef
8.
Zurück zum Zitat Schwartz MD, Rimer BK, Daly M, Sands C, Lerman C. A randomized trial of breast cancer risk counseling: the impact on self-reported mammography use. Am J Public Health. 1999;89(6):924–6.PubMedCentralPubMedCrossRef Schwartz MD, Rimer BK, Daly M, Sands C, Lerman C. A randomized trial of breast cancer risk counseling: the impact on self-reported mammography use. Am J Public Health. 1999;89(6):924–6.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Yip CH, Anderson BO. The Breast Health Global Initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries. Expert Rev Anticancer Ther. 2007;7(8):1095–104.PubMedCrossRef Yip CH, Anderson BO. The Breast Health Global Initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries. Expert Rev Anticancer Ther. 2007;7(8):1095–104.PubMedCrossRef
10.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.PubMedCrossRef Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.PubMedCrossRef
11.
Zurück zum Zitat Challa VR, Swamyvelu K, Shetty N. Assessment of the clinical utility of the Gail model in estimating the risk of breast cancer in women from the Indian population. Ecancermedicalscience. 2013;7:363.PubMedCentralPubMed Challa VR, Swamyvelu K, Shetty N. Assessment of the clinical utility of the Gail model in estimating the risk of breast cancer in women from the Indian population. Ecancermedicalscience. 2013;7:363.PubMedCentralPubMed
12.
Zurück zum Zitat Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012;14(6):R144.PubMedCentralPubMedCrossRef Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012;14(6):R144.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, et al. Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat. 2012;132(1):347–53.PubMedCrossRef Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, et al. Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat. 2012;132(1):347–53.PubMedCrossRef
14.
Zurück zum Zitat WL Beery and National Center for Health Services Research and Health Care Technology Assessment (U.S.). Health risk appraisal: methods and programs, with annotated bibliography. Rockville, MD.: U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Services Research and Health Care Technology Assessment, 1986 WL Beery and National Center for Health Services Research and Health Care Technology Assessment (U.S.). Health risk appraisal: methods and programs, with annotated bibliography. Rockville, MD.: U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Services Research and Health Care Technology Assessment, 1986
15.
Zurück zum Zitat Schoenbach VJ, Wagner EH, Karon JM. The use of epidemiologic data for personal risk assessment in health hazard/health risk appraisal programs. J Chronic Dis. 1983;30(9):625–38.CrossRef Schoenbach VJ, Wagner EH, Karon JM. The use of epidemiologic data for personal risk assessment in health hazard/health risk appraisal programs. J Chronic Dis. 1983;30(9):625–38.CrossRef
16.
Zurück zum Zitat Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25(1):10–21.PubMedCentralPubMed Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25(1):10–21.PubMedCentralPubMed
17.
Zurück zum Zitat Fang JQ. Health statistics. Beijing: People’s Medical Publishing House; 2003. p. 313. Fang JQ. Health statistics. Beijing: People’s Medical Publishing House; 2003. p. 313.
18.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.PubMedCentralCrossRef Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.PubMedCentralCrossRef
19.
Zurück zum Zitat Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.PubMedCentralPubMedCrossRef Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the Shanghai Breast Cancer study. Am J Epidemiol. 2011;174(6):661–71.PubMedCentralPubMedCrossRef Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the Shanghai Breast Cancer study. Am J Epidemiol. 2011;174(6):661–71.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618–27.PubMedCentralPubMedCrossRef Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618–27.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25(5):368–87.PubMedCrossRef Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25(5):368–87.PubMedCrossRef
23.
Zurück zum Zitat Aguilar Cordero MJ, Gonzalez Jimenez E, Alvarez Ferre J, Padilla Lopez CA, Mur Villar N, Garcia Lopez PA, et al. Breast feeding: an effective method to prevent breast cancer. Nutr Hosp. 2010;25(6):954–8.PubMed Aguilar Cordero MJ, Gonzalez Jimenez E, Alvarez Ferre J, Padilla Lopez CA, Mur Villar N, Garcia Lopez PA, et al. Breast feeding: an effective method to prevent breast cancer. Nutr Hosp. 2010;25(6):954–8.PubMed
24.
Zurück zum Zitat Pan H, He Z, Ling L, Ding Q, Chen L, Zha X, et al. Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies. Cancer Epidemiol. 2013. doi:10.1016/j.canep.2013.11.004. Pan H, He Z, Ling L, Ding Q, Chen L, Zha X, et al. Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies. Cancer Epidemiol. 2013. doi:10.​1016/​j.​canep.​2013.​11.​004.
25.
Zurück zum Zitat Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case–control and a case–case comparison. Breast Cancer Res. 2006;8(4):R39.PubMedCentralPubMedCrossRef Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case–control and a case–case comparison. Breast Cancer Res. 2006;8(4):R39.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Huang Y, Zhang X, Li W, Song F, Dai H, Wang J, et al. A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control. 2014;25(2):227–36.PubMedCrossRef Huang Y, Zhang X, Li W, Song F, Dai H, Wang J, et al. A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control. 2014;25(2):227–36.PubMedCrossRef
27.
Zurück zum Zitat Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2012;132(2):365–77.PubMedCrossRef Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2012;132(2):365–77.PubMedCrossRef
28.
Zurück zum Zitat LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337(8):536–42.PubMedCrossRef LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337(8):536–42.PubMedCrossRef
30.
Zurück zum Zitat Engelhardt EG, Garvelink MM, de Haes JH, van der Hoeven JJ, Smets EM, Pieterse AH, et al. Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol. 2014;32(3):238–50.PubMedCrossRef Engelhardt EG, Garvelink MM, de Haes JH, van der Hoeven JJ, Smets EM, Pieterse AH, et al. Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol. 2014;32(3):238–50.PubMedCrossRef
31.
Zurück zum Zitat Arrospide A, Forne C, Rue M, Tora N, Mar J, Bare M. An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain. BMC Cancer. 2013;13(1):587.PubMedCentralPubMedCrossRef Arrospide A, Forne C, Rue M, Tora N, Mar J, Bare M. An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain. BMC Cancer. 2013;13(1):587.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Gao F, Machin D, Chow KY, Sim YF, Duffy SW, Matchar DB, et al. Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple ethnic groups study). BMC Cancer. 2012;12:529.PubMedCentralPubMedCrossRef Gao F, Machin D, Chow KY, Sim YF, Duffy SW, Matchar DB, et al. Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple ethnic groups study). BMC Cancer. 2012;12:529.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695–705.PubMedCrossRef Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695–705.PubMedCrossRef
34.
Zurück zum Zitat Chay WY, Ong WS, Tan PH, Jie Leo NQ, Ho GH, Wong CS, et al. Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res. 2012;14(1):R19.PubMedCentralPubMedCrossRef Chay WY, Ong WS, Tan PH, Jie Leo NQ, Ho GH, Wong CS, et al. Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res. 2012;14(1):R19.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Dai J, Hu Z, Jiang Y, Shen H, Dong J, Ma H, et al. Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast Cancer Res. 2012;14(1):R17.PubMedCentralPubMedCrossRef Dai J, Hu Z, Jiang Y, Shen H, Dong J, Ma H, et al. Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast Cancer Res. 2012;14(1):R17.PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Von Euler-Chelpin M, Olsen AH, Njor S, Jensen A, Vejborg I, Schwartz W, et al. Does educational level determine screening participation? Eur J Cancer Prev. 2008;17(3):273–8.CrossRef Von Euler-Chelpin M, Olsen AH, Njor S, Jensen A, Vejborg I, Schwartz W, et al. Does educational level determine screening participation? Eur J Cancer Prev. 2008;17(3):273–8.CrossRef
37.
Zurück zum Zitat Woloshin S, Schwartz LM. The U.S. Postal Service and cancer screening—stamps of approval? N Engl J Med. 1999;340(11):884–7.PubMedCrossRef Woloshin S, Schwartz LM. The U.S. Postal Service and cancer screening—stamps of approval? N Engl J Med. 1999;340(11):884–7.PubMedCrossRef
38.
Zurück zum Zitat Kye SY, Park K, Park HG, Kim MH. Psychological impact of health risk appraisal of Korean women at different levels of breast cancer risk: neglected aspect of the web-based cancer risk assessment tool. Asian Pac J Cancer Prev. 2012;13(2):437–41.PubMedCrossRef Kye SY, Park K, Park HG, Kim MH. Psychological impact of health risk appraisal of Korean women at different levels of breast cancer risk: neglected aspect of the web-based cancer risk assessment tool. Asian Pac J Cancer Prev. 2012;13(2):437–41.PubMedCrossRef
39.
Zurück zum Zitat Groenvold M. Health-related quality of life in early breast cancer. Dan Med Bull. 2010;57(9):B4184.PubMed Groenvold M. Health-related quality of life in early breast cancer. Dan Med Bull. 2010;57(9):B4184.PubMed
40.
Zurück zum Zitat Gaston-Johansson F, Ohly KV, Fall-Dickson JM, Nanda JP, Kennedy MJ. Pain, psychological distress, health status, and coping in patients with breast cancer scheduled for autotransplantation. Oncol Nurs Forum. 1999;26(8):1337–45.PubMed Gaston-Johansson F, Ohly KV, Fall-Dickson JM, Nanda JP, Kennedy MJ. Pain, psychological distress, health status, and coping in patients with breast cancer scheduled for autotransplantation. Oncol Nurs Forum. 1999;26(8):1337–45.PubMed
Metadaten
Titel
Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women
verfasst von
Yuan Wang
Ying Gao
Munkhzul Battsend
Kexin Chen
Wenli Lu
Yaogang Wang
Publikationsdatum
01.11.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 11/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1967-0

Weitere Artikel der Ausgabe 11/2014

Tumor Biology 11/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.